Full text is available at the source.
Abstract
GLP-1 receptor agonists may significantly reduce cardiovascular risk in individuals with overweight or obesity, independent of weight loss.
- Obesity is linked to increased cardiovascular morbidity and mortality.
- Lifestyle interventions often lead to only modest long-term weight loss and limited weight maintenance.
- Bariatric surgery is not suitable for all patients, and many experience substantial weight regain.
- GLP-1 receptor agonists improve weight reduction and cardiometabolic risks by enhancing insulin secretion and suppressing appetite.
- Large trials indicate GLP-1 receptor agonists reduce major adverse cardiovascular events and all-cause mortality in individuals with type 2 diabetes.
- Semaglutide, a GLP-1 receptor agonist, has shown significant cardiovascular risk reduction in overweight or obese populations without diabetes.
Simplified